TrialAntimicrobial agents and chemotherapy2022

Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Expression Inhibitor GST-HG131 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial.

Xiaojiao Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.